Nanology Labs has developed a tumor modulating theranostic agent, Manganescan, with capability to oxygenate tumors and kill cancer cells in combination with radiation therapy. This product is also able to detect early stage tumors with high accuracy using MRI. The combination of Manganescan with radiation therapy can improve the life-expectancy by 5-fold and achieve 40% cure rate. Manganescan offers a safer and effective approach to treat solid tumors via minimalizing the total radiation doses and the risk to normal tissues and presenting a broad applicability across multiple tumor types.

Nanology Labs logo



Event details

Date: September 14 - 16, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


16 in total